BioCryst Pharmaceuticals, Inc.
|
2190 Parkway Lake Drive
Birmingham, AL 35244
United States |
| Tel: |
1/205 444-4600 |
| URL: |
http://www.biocryst.com |
|
 |
| Primary Symbols & Exchanges: |
| BCRX - NASDAQ |
| - Berlin-Bremen Stock Exchange |
|
|
| Primary Industry: |
| Biotechnology |
|
|
SIC Industry Code:
|
|
NAICS Industry Code:
|
|
Thomson Financial Business Description:
| The Company's principal activity is to design, optimize and develop novel small molecule pharmaceuticals that block key enzymes essential for cancer, cardiovascular diseases, autoimmune diseases and viral infections. The Company's most advanced drug candidate, forodesine hydrochloride ('BCX-1777' or 'forodesine'), is an investigational purine nucleoside phosphorylase ('PNP') inhibitor for the treatment of T-cell mediated disorders. Some of the projects under development include PNP Inhibitor (forodesine HCl, BCX-1777), Oncology, PNP Inhibitor (BCX-4208), Hepatitis C Polymerase Inhibitors, Tissue Factor/Factor VIIa Inhibitors. The Company markets its products through collaborators and licensees. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on BioCryst Pharmaceuticals, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
